2021 Fiscal Year Final Research Report
Suicide gene therapy using mesenchymal stem cells for brain tumors
Project/Area Number |
19K09504
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 56010:Neurosurgery-related
|
Research Institution | Hamamatsu University School of Medicine |
Principal Investigator |
Amano Shinji 浜松医科大学, 医学部, 特任研究員 (70464138)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 自殺遺伝子療法 / 脳腫瘍 / 間葉系幹細胞 / 脂肪細胞 |
Outline of Final Research Achievements |
We researched suicide gene therapy to the malignant brain tumor which has difficulty in treatment, using adipose mesenchymal stem cell(ADMSC)/ganciclovir(GCV). First mesenchymal stem cell was separated from a SD rat fat cell. Treatment was tried using ADMSC which introduced herpes simplex virus-thymidine kinase(ADMSCtk) to a rat C6 brain tumor cell. In vitro, the cell ratio of ADMSCtk:C6 also indicated anti-tumor effect in 1:16, and the perfect tumor grave effect was obtained in 1:8. In vivo, the tumor volume reduction effect and the extension of a survival curve were confirmed by a study using a rat. ADMSCtk/GCV treatment will be effective.
|
Free Research Field |
脳腫瘍
|
Academic Significance and Societal Importance of the Research Achievements |
今まで我々は一貫して、自殺遺伝子療法を用いた脳腫瘍の治療研究にあたってきた。その中で、安定的に供給できるベクターの選択が問題であった。今回、自己からも容易に採取できる脂肪細胞を用いることにより、より臨床への発展が期待できるものとなっている。脂肪細胞由来の間葉系幹細胞を用いることは、今後、他の伝子治療のベクターとして用いることができる可能性を広げるだけでなく、自己由来細胞での治療や再生医療にも応用ができる可能性がある。
|